Applications of SARS-CoV-2 serological testing: impact of test performance, sample matrices, and patient characteristics

被引:4
作者
Fung, Chun Yiu Jordan [1 ,2 ]
Scott, Mackenzie [1 ,2 ,3 ]
Lerner-Ellis, Jordan [1 ,2 ,3 ]
Taher, Jennifer [2 ,3 ,4 ]
机构
[1] Sinai Hlth, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[2] Sinai Hlth, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Sinai Hlth, Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada
关键词
SARS-CoV-2; COVID-19; serology; immunity; antibody; INTERNATIONAL STANDARD; COVID-19; ANTIBODY; INFECTION; KINETICS;
D O I
10.1080/10408363.2023.2254390
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Laboratory testing has been a key tool in managing the SARS-CoV-2 global pandemic. While rapid antigen and PCR testing has proven useful for diagnosing acute SARS-CoV-2 infections, additional testing methods are required to understand the long-term impact of SARS-CoV-2 infections on immune response. Serological testing, a well-documented laboratory practice, measures the presence of antibodies in a sample to uncover information about host immunity. Although proposed applications of serological testing for clinical use have previously been limited, current research into SARS-CoV-2 has shown growing utility for serological methods in these settings. To name a few, serological testing has been used to identify patients with past infections and long-term active disease and to monitor vaccine efficacy. Test utility and result interpretation, however, are often complicated by factors that include poor test sensitivity early in infection, lack of immune response in some individuals, overlying infection and vaccination responses, lack of standardization of antibody titers/levels between instruments, unknown titers that confer immune protection, and large between-individual biological variation following infection or vaccination. Thus, the three major components of this review will examine (1) factors that affect serological test utility: test performance, testing matrices, seroprevalence concerns and viral variants, (2) patient factors that affect serological response: timing of sampling, age, sex, body mass index, immunosuppression and vaccination, and (3) informative applications of serological testing: identifying past infection, immune surveillance to guide health practices, and examination of protective immunity. SARS-CoV-2 serological testing should be beneficial for clinical care if it is implemented appropriately. However, as with other laboratory developed tests, use of SARS-CoV-2 serology as a testing modality warrants careful consideration of testing limitations and evaluation of its clinical utility.
引用
收藏
页码:70 / 88
页数:19
相关论文
共 184 条
  • [51] Determinants of IgG antibodies kinetics after severe and critical COVID-19
    De Greef, Julien
    Scohy, Anais
    Zech, Francis
    Aboubakar, Frank
    Pilette, Charles
    Gerard, Ludovic
    Pothen, Lucie
    Yildiz, Halil
    Belkhir, Leila
    Yombi, Jean Cyr
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (09) : 5416 - 5424
  • [52] Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
    Delgado, Juan F.
    Berenguer-Llergo, Antoni
    Julia, Germa
    Navarro, Gema
    Espasa, Mateu
    Rodriguez, Sara
    Sanchez, Noemi
    Van den Eynde, Eva
    Navarro, Marta
    Calvet, Joan
    Gratacos, Jordi
    Serrano, Rosa M.
    Pena, Pilar
    Amengual, Maria J.
    [J]. VIRUSES-BASEL, 2022, 14 (06):
  • [53] Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection among Veterans Affairs healthcare system employees suggests higher risk of infection when exposed to SARS-CoV-2 outside the work environment
    Dimcheff, Derek E.
    Schildhouse, Richard J.
    Hausman, Mark S., Jr.
    Vincent, Brenda M.
    Markovitz, Erica
    Chensue, Stephen W.
    Deng, Jane
    McLeod, Melissa
    Hagan, Danielle
    Russell, Jon
    Bradley, Suzanne F.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2021, 42 (04) : 392 - 398
  • [54] A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
    Dougan, Michael
    Azizad, Masoud
    Mocherla, Bharat
    Gottlieb, Robert L.
    Chen, Peter
    Hebert, Corey
    Perry, Russell
    Boscia, Joseph
    Heller, Barry
    Morris, Jason
    Crystal, Chad
    Igbinadolor, Awawu
    Huhn, Gregory
    Cardona, Jose
    Shawa, Imad
    Kumar, Princy
    Blomkalns, Andra
    Adams, Andrew C.
    Van Naarden, Jacob
    Custer, Kenneth L.
    Knorr, Jack
    Oakley, Gerard
    Schade, Andrew E.
    Holzer, Timothy R.
    Ebert, Philip J.
    Higgs, Richard E.
    Sabo, Janelle
    Patel, Dipak R.
    Dabora, Matan C.
    Williams, Mark
    Klekotka, Paul
    Shen, Lei
    Skovronsky, Daniel M.
    Nirula, Ajay
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E440 - E449
  • [55] Ebell MH, 2020, AM FAM PHYSICIAN, V102, P5
  • [56] Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for SARS-CoV-2 During Pregnancy
    Edlow, Andrea G.
    Castro, Victor M.
    Shook, Lydia L.
    Kaimal, Anjali J.
    Perlis, Roy H.
    [J]. JAMA NETWORK OPEN, 2022, 5 (06) : E2215787
  • [57] fda.gov, 2023, SARS COV 2 VIR MUT I
  • [58] Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection
    Fogh, Kamille
    Larsen, Tine Graakjaer
    Hansen, Cecilie B.
    Hasselbalch, Rasmus B.
    Eriksen, Alexandra R. R.
    Bundgaard, Henning
    Frikke-Schmidt, Ruth
    Hilsted, Linda M.
    Ostergaard, Lars
    Johansen, Isik S.
    Hageman, Ida
    Garred, Peter
    Iversen, Kasper
    [J]. MICROBIOLOGY SPECTRUM, 2022, 10 (06):
  • [59] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
    Folegatti, Pedro M.
    Ewer, Katie J.
    Aley, Parvinder K.
    Angus, Brian
    Becker, Stephan
    Belij-Rammerstorfer, Sandra
    Bellamy, Duncan
    Bibi, Sagida
    Bittaye, Mustapha
    Clutterbuck, Elizabeth A.
    Dold, Christina
    Faust, Saul N.
    Finn, Adam
    Flaxman, Amy L.
    Hallis, Bassam
    Heath, Paul
    Jenkin, Daniel
    Lazarus, Rajeka
    Makinson, Rebecca
    Minassian, Angela M.
    Pollock, Katrina M.
    Ramasamy, Maheshi
    Robinson, Hannah
    Snape, Matthew
    Tarrant, Richard
    Voysey, Merryn
    Green, Catherine
    Douglas, Alexander D.
    Hill, Adrian V. S.
    Lambe, Teresa
    Gilbert, Sarah C.
    Pollard, Andrew J.
    [J]. LANCET, 2020, 396 (10249) : 467 - 478
  • [60] Antibody tests for identification of current and past infection with SARSCoV-2
    Fox, Tilly
    Geppert, Julia
    Dinnes, Jacqueline
    Scandrett, Katie
    Bigio, Jacob
    Sulis, Giorgia
    Hettiarachchi, Dineshani
    Mathangasinghe, Yasith
    Weeratunga, Praveen
    Wickramasinghe, Dakshitha
    Bergman, Hanna
    Buckley, Brian S.
    Probyn, Katrin
    Sguassero, Yanina
    Davenport, Clare
    Cunningham, Jane
    Dittrich, Sabine
    Emperador, Devy
    Hoo, Lotty
    Leeflang, Mariska M. G.
    McInnes, Matthew D. F.
    Spijker, Rene
    Struyf, Thomas
    Van den Bruel, Ann
    Verbakel, Jan Y.
    Takwoingi, Yemisi
    Taylor-Phillips, Sian
    Deeks, Jonathan J.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (11):